Systolic Heart Failure disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SYS003 MIFTS: 45	Systolic Heart Failure Categories: Cardiovascular diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Systolic Heart Failure

MalaCards integrated aliases for Systolic Heart Failure:

Name: Systolic Heart Failure ¹¹ ⁵ ¹⁴ ¹⁶

Heart Failure, Systolic ⁴³ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:9651

ICD9CM ³⁴ 428.2

MeSH ⁴³ D054143

SNOMED-CT ⁶⁸ 417996009

EFO ¹⁶ EFO_1001207

UMLS ⁷¹ C1135191

Sources

Summaries for Systolic Heart Failure

MalaCards based summary: Systolic Heart Failure, also known as heart failure, systolic, is related to peripartum cardiomyopathy and central sleep apnea. An important gene associated with Systolic Heart Failure is MIR423 (MicroRNA 423), and among its related pathways/superpathways are Cardiac conduction and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Verapamil and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and kidney, and related phenotypes are muscle and homeostasis/metabolism

Sources

Related Diseases for Systolic Heart Failure

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 513)

#	Related Disease	Score	Top Affiliating Genes
1	peripartum cardiomyopathy	31.8	TTN NR3C2 NPPB MYH6 MIR423 ACE
2	central sleep apnea	31.0	REN NPPB CRP ACE
3	sleep apnea	30.7	REN NPPB IL6 EDN1 CRP ACE
4	atrial fibrillation	30.6	TNNI3 NR3C2 NPPB IL6 CRP AGTR1
5	left bundle branch hemiblock	30.5	TTN TNNT2 TNNI3 REN NR3C2 NPPB
6	deficiency anemia	30.5	SERPINA3 REN MME IL6 CRP ACE
7	rheumatic heart disease	30.5	NPPB IL6 ACE
8	cardiomyopathy, familial hypertrophic, 1	30.5	TTN TNNT2 TNNI3 MYH6
9	nutritional deficiency disease	30.5	SERPINA3 IL6 CRP
10	hypothyroidism	30.4	REN NPPB LGALS3 CRP ACE
11	chagas disease	30.4	NPPB LGALS3 IL6 ADRB1 ACE
12	uremia	30.4	REN IL6 CRP ACE
13	pulmonary disease, chronic obstructive	30.4	SERPINA3 PDE5A NPPB IL6 CRP ACE
14	pure autonomic failure	30.3	REN PDE5A ACE
15	mitral valve insufficiency	30.3	TTN TNNT2 TNNI3 REN NR3C2 NPPB
16	wild-type amyloidosis	30.3	SERPINA3 NPPB
17	apnea, obstructive sleep	30.3	REN NR3C2 NPPB IL6 EDN1 CRP
18	acute kidney failure	30.3	REN IL6 ACE
19	cardiac arrest	30.2	TNNT2 TNNI3 NPPB CRP ACE
20	kidney disease	30.2	REN NR3C2 NPPB IL6 EDN1 CRP
21	angina pectoris	30.2	TNNI3 NPPB IL6 EDN1 CRP ACE
22	autonomic nervous system disease	30.2	REN IL6 CRP ACE
23	amyloidosis	30.1	SERPINA3 NPPB MME IL6 CRP
24	gastroenteritis	30.1	REN IL6 CRP
25	pulmonary hypertension	30.1	REN PDE5A NPPB IL6 EDN1 CRP
26	polycythemia	30.1	REN EDN1 CRP ACE
27	sleep disorder	30.1	REN IL6 EDN1 CRP ACE
28	atrioventricular block	30.1	TNNT2 TNNI3 NPPB MYH6 CRP ACE
29	vascular disease	30.1	PDE5A IL6 EDN1 CRP AGTR1 ACE
30	intermittent claudication	30.1	TNNT2 IL6 CRP ACE
31	coronary stenosis	30.0	TNNI3 NPPB IL6 CRP ACE
32	peripheral vascular disease	30.0	SERPINA3 REN PDE5A IL6 EDN1 CRP
33	peripheral artery disease	29.9	REN NPPB MIR423 IL6 CRP ACE
34	arteries, anomalies of	29.9	TNNI3 SERPINA3 REN MIR423 IL6 EDN1
35	acute myocarditis	29.9	TNNT2 TNNI3 REN NPPB IL6 CRP
36	pericardial effusion	29.9	TNNT2 TNNI3 REN NPPB IL6 CRP
37	chronic kidney disease	29.8	TNNT2 TNNI3 REN NR3C2 NPPB IL6
38	transient cerebral ischemia	29.8	SERPINA3 REN NPPB IL6 CRP ACE
39	lung disease	29.8	SERPINA3 NPPB IL6 EDN1 ACE
40	liver cirrhosis	29.8	SERPINA3 REN IL6 EDN1
41	atherosclerosis susceptibility	29.8	IL6 EDN1 CRP AGTR1 ACE
42	pulmonary valve insufficiency	29.8	REN PDE5A NPPB EDN1 CRP ACE
43	myopathy	29.7	TTN TNNT2 TNNI3 SERPINA3 MYH6 MIR423
44	tricuspid valve insufficiency	29.7	TNNT2 TNNI3 REN PDE5A NR3C2 NPPB
45	lipid metabolism disorder	29.7	SERPINA3 REN PDE5A IL6 EDN1 CRP
46	pulmonary edema	29.7	TNNT2 TNNI3 REN NPPB EDN1 CRP
47	myocarditis	29.6	TTN TNNT2 TNNI3 NPPB MYH6 IL6
48	conn's syndrome	29.6	REN NR3C2 IL6 EDN1 CRP AGTR1
49	aortic valve disease 1	29.5	REN NPPB MYH6 MIR423 EDN1 CRP
50	connective tissue disease	29.5	SERPINA3 MIR92B MIR423 IL6 EDN1 CRP

Graphical network of the top 20 diseases related to Systolic Heart Failure:

Sources

Symptoms & Phenotypes for Systolic Heart Failure

MGI Mouse Phenotypes related to Systolic Heart Failure:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	muscle	MP:0005369	9.85	ADRB1 EDN1 IL6 MYH6 NPPB NR3C2
2	homeostasis/metabolism	MP:0005376	9.8	ACE ADRB1 AGTR1 CRP EDN1 IL6
3	cardiovascular system	MP:0005385	9.47	ACE ADRB1 AGTR1 CRP EDN1 IL6

Sources

Drugs & Therapeutics for Systolic Heart Failure

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Verapamil

Approved

Phase 4

152-11-4, 52-53-9

2520

Carvedilol

Approved, Investigational

Phase 4

72956-09-3

2585

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Lisinopril

Approved, Investigational

Phase 4

83915-83-7, 76547-98-3

5362119

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 11128-99-7, 4474-91-3

172198

Bisoprolol

Approved

Phase 4

66722-44-9

2405

Canagliflozin

Approved

Phase 4

842133-18-0

74323022 24812758

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Enalaprilat

Approved

Phase 4

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 4

75847-73-3

40466924 5388962 5362032

Hydralazine

Approved

Phase 4

86-54-4

3637

Iron

Approved

Phase 4

7439-89-6

29936

Eplerenone

Approved

Phase 4

107724-20-9

443872

Spironolactone

Approved

Phase 4

1952-01-7, 52-01-7

5833

Simendan

Investigational

Phase 4

131741-08-7

calcium channel blockers

Phase 4

Angiotensin Receptor Antagonists

Phase 4

Sacubitril and valsartan sodium hydrate drug combination

Phase 4

Angiotensinogen

Phase 4

16133225

HIV Protease Inhibitors

Phase 4

Giapreza

Phase 4

protease inhibitors

Phase 4

Adrenergic beta-1 Receptor Antagonists

Phase 4

Adrenergic Antagonists

Phase 4

Neurotransmitter Agents

Phase 4

Sympatholytics

Phase 4

Sitagliptin Phosphate

Phase 4

654671-77-9

Dipeptidyl-Peptidase IV Inhibitors

Phase 4

Incretins

Phase 4

Purinergic P2Y Receptor Antagonists

Phase 4

Prasugrel Hydrochloride

Phase 4

389574-19-0

Platelet Aggregation Inhibitors

Phase 4

Angiotensin II Type 1 Receptor Blockers

Phase 4

Angiotensin-Converting Enzyme Inhibitors

Phase 4

Chrysarobin

Phase 4

Adrenergic beta-Antagonists

Phase 4

Adrenergic Agents

Phase 4

Antihypertensive Agents

Phase 4

Mineralocorticoids

Phase 4

Mineralocorticoid Receptor Antagonists

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Diuretics, Potassium Sparing

Phase 4

diuretics

Phase 4

Vasodilator Agents

Phase 4

Cardiotonic Agents

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Phosphodiesterase 3 Inhibitors

Phase 4

Interventional clinical trials:

(show top 50) (show all 187)

#	Name	Status	NCT ID	Phase	Drugs
1	Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations	Unknown status	NCT03764722	Phase 4	Levosimendan
2	Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial	Unknown status	NCT03096613	Phase 4	Levothyroxine
3	Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial	Unknown status	NCT01612260	Phase 4	Shensong Yangxin capsule;placebo Capsule
4	Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism	Unknown status	NCT02316743	Phase 4	Levothyroxine supplementation
5	The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF).	Unknown status	NCT03871699	Phase 4	Ferric carboxymaltose
6	Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy	Unknown status	NCT00348530	Phase 4	Verapamil
7	Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins	Unknown status	NCT02797340	Phase 4	Metformin
8	Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial	Unknown status	NCT02579200	Phase 4
9	Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®	Unknown status	NCT04570865	Phase 4	Dapagliflozin
10	Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton	Unknown status	NCT03553303	Phase 4	Sacubitril / Valsartan Oral Tablet
11	Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.	Unknown status	NCT03392740	Phase 4	Lisinopril;Placebo Oral Tablet
12	Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM)	Completed	NCT01074307	Phase 4	Low Dose Bisoprolol;High Dose Bisoprolol
13	A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure	Completed	NCT02920918	Phase 4	Canagliflozin;Sitagliptin
14	Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure	Completed	NCT01765400	Phase 4	Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks
15	SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients.	Completed	NCT01434615	Phase 4
16	Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure	Completed	NCT02903225	Phase 4
17	Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial	Completed	NCT02401126	Phase 4
18	Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction	Completed	NCT05387967	Phase 4	Sacubitril/valsartan
19	Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF).	Completed	NCT02970669	Phase 4	sacubitril/valsartan (LCZ696);enalapril;matching placebo sacubitril/valsartan (LCZ696);matching placebo enalapril
20	The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation	Recruiting	NCT04217135	Phase 4	evidence-based medications vs. high-dose hydralazine + evidence-based medications
21	Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2	Recruiting	NCT03036462	Phase 4	Iron;Saline
22	Pulse Reduction On Beta-blocker and Ivabradine Therapy	Active, not recruiting	NCT02973594	Phase 4	Ivabradine;Placebo
23	Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments?	Enrolling by invitation	NCT03984591	Phase 4	Eplerenone;Spironolactone
24	Levosimendan In Ambulatory Heart Failure Patients	Not yet recruiting	NCT04705337	Phase 4	Levosimendan
25	Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure	Unknown status	NCT01913847	Phase 3	Sildenafil;Placebo
26	Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）	Unknown status	NCT02188082	Phase 2, Phase 3	IvabRadine hemisulfate Sustained-release Tablets;placebo
27	MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy	Unknown status	NCT01640769	Phase 3
28	Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure	Unknown status	NCT01639378	Phase 3
29	The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia	Completed	NCT02998697	Phase 2, Phase 3	Ferrous Sulfate;Placebo Oral Capsule
30	Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure	Completed	NCT00206310	Phase 3	CRESTOR
31	The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure	Completed	NCT00232180	Phase 3	Eplerenone
32	Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients	Completed	NCT02809131	Phase 3	polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
33	Spinal Cord Stimulation For Heart Failure As A Restorative Treatment	Completed	NCT01362725	Phase 2, Phase 3
34	A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction	Completed	NCT03917459	Phase 3	LCZ696;Enalapril matching placebo;Enalapril;LCZ696 matching placebo
35	Blended Collaborative Care for Heart Failure and Co-Morbid Depression	Completed	NCT02044211	Phase 2, Phase 3
36	Growth Hormone Treatment in Patients With Ischemic Heart Failure and Circulating Levels of NT-proBNP	Completed	NCT04420481	Phase 3	Somatropin;Placebo
37	Cardiovascular Effects of Preferred Home-based Exercise Training and Extended Adherence Measures in Systolic Heart Failure - Pilot Study	Recruiting	NCT02051712	Phase 3
38	A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.	Recruiting	NCT03388593	Phase 3	rhNRG-1;Placebo
39	Investigator-initiated, Randomized, Double-blind, Controlled, Multi-center Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency	Recruiting	NCT03991000	Phase 3	Ferric carboxymaltose;Saline
40	Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life	Recruiting	NCT04201015	Phase 2, Phase 3
41	A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy	Active, not recruiting	NCT04468529	Phase 3	Recombinant human Neuregulin for injection;Placebo
42	A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure	Terminated	NCT01131637	Phase 3	rhNRG-1;placebo
43	Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure	Terminated	NCT01646515	Phase 3	Placebo;Udenafil (Zydena)
44	A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure	Terminated	NCT01214096	Phase 3	rhNRG-1;placebo
45	A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure	Terminated	NCT01439789	Phase 3	rhNRG-1;Placebo
46	A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure	Terminated	NCT01541202	Phase 3	rhNRG-1;Placebo
47	A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure	Terminated	NCT01439893	Phase 3	rhNRG-1;Placebo
48	MADIT ASIA Cardiac Resynchronization Trial (MADIT-ASIA)	Terminated	NCT01872234	Phase 3
49	GutHeart: Targeting Gut Microbiota to Treat Heart Failure	Unknown status	NCT02637167	Phase 2	Rifaximin;Saccharomyces boulardii
50	A Double Blinded, Placebo Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Acute Cardiovascular Responses of a 7 Day Oral Treatment With the Partial Adenosine A1 Receptor Agonist BAY1067197 in Patients With Chronic Systolic Heart Failure: the PARSiFAL-pilot Study.	Completed	NCT02040233	Phase 2	BAY1067197 (10 mg);BAY1067197;Placebo (10 mg);Placebo

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Sources

Genetic Tests for Systolic Heart Failure

Sources

Anatomical Context for Systolic Heart Failure

Organs/tissues related to Systolic Heart Failure:

MalaCards : Heart, Brain, Kidney, Spinal Cord, Endothelial, Breast, Skeletal Muscle

Sources

Publications for Systolic Heart Failure

Articles related to Systolic Heart Failure:

(show top 50) (show all 2539)

#	Title	Authors	PMID	Year
1	Effect of adaptive servo ventilation on central sleep apnea and sleep structure in systolic heart failure patients: polysomnography data from the SERVE-HF major sub study. ⁶²	Tamisier R...Woehrle H	35840352	2022
2	Insights into the Mechanism of the Cardiac Drug Omecamtiv Mecarbil─A Computational Study. ⁶²	Chakraborti A...Schwartz SD	36448224	2022
3	dATP elevation induces myocardial metabolic remodeling to support improved cardiac function. ⁶²	Mhatre KN...Regnier M	36470336	2022
4	Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study. ⁶²	Fastner C...Kuschyk J	36056955	2022
5	Sepsis, Septic Shock, and Differences in Cardiovascular Event Occurrence. ⁶²	Falk GE...Vindhyal MR	35236176	2022
6	Early predicting improvement of severe systolic heart failure by left atrial volume. ⁶²	Hsiao CS...Chiou KR	36409354	2022
7	Myocardial fibrosis and ventricular ectopy in patients with non-ischemic systolic heart failure: results from the DANISH trial. ⁶²	Elming MB...Thune JJ	36434345	2022
8	Pulmonary artery-to-aorta ratio on high-resolution computed tomography and exercise performance in systolic heart failure. ⁶²	Basso L...Muller PT	35588892	2022
9	Oral N-acetylcysteine as an adjunct to standard medical therapy improved heart function in cases with stable class II and III systolic heart failure. ⁶²	Yazdi A...Zareie S	34727343	2022
10	Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry. ⁶²	Spinarova M...Labr K	36295637	2022
11	Effect of adaptive servo-ventilation for central sleep apnoea in systolic heart failure on muscle sympathetic nerve activity: a SERVE-HF randomised ancillary study. ⁶²	Tamisier R...Levy P	36229051	2022
12	Long-term events following catheter-ablation for atrial fibrillation in heart failure with preserved ejection fraction. ⁶²	Ishiguchi H...Yano M	35894764	2022
13	Using the C2HEST Score for Predicting Postoperative Atrial Fibrillation After Cardiac Surgery: A Report From the Western Denmark Heart Registry, the Danish National Patient Registry, and the Danish National Prescription Registry. ⁶²	Rasmussen LF...Lip GYH	35581051	2022
14	Dilated Cardiomyopathy and Systolic Heart Failure in a Female Patient With Danon Disease. ⁶²	Stack-Pyle TJ...Arcara V	36447708	2022
15	The serum concentration of brain‑derived neurotrophic factor is lower in ambulatory and clinically stable patients with more advanced systolic heart failure. ⁶²	Pytka MJ...Guzik P	35916461	2022
16	Cardiac resynchronization therapy response in cardiac sarcoidosis. ⁶²	Shabtaie SA...Deshmukh AJ	35870183	2022
17	Unsupervised machine learning demonstrates the prognostic value of TAPSE/PASP ratio among hospitalized patients with COVID-19. ⁶²	Jani V...Mukherjee M	35907784	2022
18	Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure. ⁶²	Imamura T...Kinugawa K	36142977	2022
19	Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial. ⁶²	Butt JH...Kober L	35942877	2022
20	Association between DLCO index and the severity of heart failure: a cross-sectional study. ⁶²	Izadi S...Bakhtiyari M	36082926	2022
21	Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair. ⁶²	Borges JI...Lymperopoulos A	34983911	2022
22	Dapagliflozin for patients with heart failure and reduced ejection fraction. ⁶²	Ferry A	36007119	2022
23	Effects of adaptive left bundle branch-optimized cardiac resynchronization therapy: a single centre experience. ⁶²	Feng XF...Li YG	35933334	2022
24	For the love of muscles: a bodybuilder with complicated left ventricular heart failure. ⁶²	De Turck L...Vonck A	35972452	2022
25	Society for Maternal-Fetal Medicine Consult Series #61: Anticoagulation in pregnant patients with cardiac disease. ⁶²	Society for Maternal-Fetal Medicine (SMFM). Electronic address: [email protected] Committee	35337804	2022
26	A strange way of breathing in a patient with advanced systolic heart failure. ⁶²	Mapelli M...Agostoni P	35953097	2022
27	Poor efficacy of oral iron replacement therapy in pediatric patients with heart failure. ⁶²	Puri K...Price JF	34629125	2022
28	Identification of Potential Biomarkers Associated with Dilated Cardiomyopathy by Weighted Gene Coexpression Network Analysis. ⁶²	Guo Q...Li X	36042172	2022
29	Impact of signal-averaged electrocardiography findings on appropriate shocks in prophylactic implantable cardioverter defibrillator patients with nonischemic systolic heart failure. ⁶²	Nomoto M...Hagiwara N	35974317	2022
30	Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure. ⁶²	Ye F...FIRST Investigators	35926931	2022
31	Effects of Renin-Angiotensin-Aldosterone System Inhibition on Left Ventricular Hypertrophy, Diastolic Function, and Functional Status in Patients With Hypertrophic Cardiomyopathy: A Systematic Review. ⁶²	Akhtar H...Elkholy K	35949750	2022
32	Left bundle branch pacing in a ventricular pacing dependent patient with heart failure: A case report. ⁶²	Song BX...Zhang YY	36051124	2022
33	First-in-man Implantation of a Cardiac Microcurrent Device for Chronic Systolic Heart Failure. ⁶²	Schmitto JD...Haverich A	34324448	2022
34	Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial. ⁶²	Bundgaard H...Vissing CR	35758031	2022
35	ln silico simulation of the interaction among autoregulatory mechanisms regulating cerebral blood flow rate in the healthy and systolic heart failure conditions during exercise. ⁶²	Bozkurt S...Ayten UE	35508787	2022
36	Efficacy of Doppler echocardiography-guided ivabradine therapy. ⁶²	Izumida T...Kinugawa K	35789418	2022
37	Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure. ⁶²	Mihalick V...Van Tassell B	35473780	2022
38	[Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.] ⁶²	Ageev FT	35989624	2022
39	Hemodynamic and Clinical Determinants of Left Atrial Enlargement in Liver Transplant Candidates. ⁶²	Remillard TC...Tedford RJ	35341576	2022
40	In nonischemic systolic HF, prophylactic ICDs did not reduce all-cause mortality vs. usual care at 10 y. ⁶²	Sestier M...Leong D	35667075	2022
41	Pathophysiologic mechanisms of lupus-induced myocardial injury elucidated by cardiovascular magnetic resonance imaging. ⁶²	Babar N...Saba SG	35303625	2022
42	An Unusual Case of Dilated Cardiomyopathy in Wegner's Granulomatosis. ⁶²	Khatri Chhetri RC...Zahra F	35832755	2022
43	In-Hospital Outcomes in Pregnancy After Heart Transplantation. ⁶²	DeFilippis EM...Kittleson M	35331474	2022
44	Predictive Value of C2HEST Score for Atrial Fibrillation Recurrence Following Successful Cryoballoon Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation. ⁶²	Levent F...Tutuncu A	35583221	2022
45	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. ⁶²	Neuen BL...Heerspink HJL	35394821	2022
46	Selvester QRS score predicts improvement of LVEF in atrial fibrillation patients with systolic heart failure. ⁶²	Nomura Y...Izawa H	35383970	2022
47	Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice. ⁶²	Davis LE...Pogge EK	34459280	2022
48	Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure. ⁶²	Vest AR...Saltzman E	35378982	2022
49	Aerobic exercise and telomere length in patients with systolic heart failure: protocol study for a randomized controlled trial. ⁶²	Franzoni LT...Stein R	35410445	2022
50	Echocardiographic Parameters and Outcomes in Methamphetamine-Associated Heart Failure: A Propensity Score-Weighted Analysis. ⁶²	Kewcharoen J...Abramov D	35465084	2022

Sources

Genes for Systolic Heart Failure

Genes related to Systolic Heart Failure (0 elite genes):

(show all 26)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR423	MicroRNA 423	RNA Gene	8.75	DISEASES inferred ¹⁴ ¹⁴
2	MIR92B	MicroRNA 92b	RNA Gene	8.26	DISEASES inferred ¹⁴ ¹⁴
3	ACE	Angiotensin I Converting Enzyme	Protein Coding	8.07	DISEASES inferred ¹⁴
4	NPPB	Natriuretic Peptide B	Protein Coding	7.46	DISEASES inferred ¹⁴
5	REN	Renin	Protein Coding	7.31	DISEASES inferred ¹⁴
6	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	7.29	DISEASES inferred ¹⁴
7	MIR1306	MicroRNA 1306	RNA Gene	7.15	DISEASES inferred ¹⁴ ¹⁴
8	MME	Membrane Metalloendopeptidase	Protein Coding	6.36	DISEASES inferred ¹⁴
9	TTN	Titin	Protein Coding	6.18	DISEASES inferred ¹⁴
10	CRP	C-Reactive Protein	Protein Coding	6.17	DISEASES inferred ¹⁴
11	TNNI3	Troponin I3, Cardiac Type	Protein Coding	5.98	DISEASES inferred ¹⁴
12	MYH6	Myosin Heavy Chain 6	Protein Coding	5.96	DISEASES inferred ¹⁴
13	LGALS3	Galectin 3	Protein Coding	5.94	DISEASES inferred ¹⁴
14	AGTR1	Angiotensin II Receptor Type 1	Protein Coding	5.9	DISEASES inferred ¹⁴
15	ADRB1	Adrenoceptor Beta 1	Protein Coding	5.83	DISEASES inferred ¹⁴
16	SERPINA3	Serpin Family A Member 3	Protein Coding	5.75	DISEASES inferred ¹⁴ ¹⁴
17	PDE5A	Phosphodiesterase 5A	Protein Coding	5.74	DISEASES inferred ¹⁴
18	TNNT2	Troponin T2, Cardiac Type	Protein Coding	5.69	DISEASES inferred ¹⁴
19	IL6	Interleukin 6	Protein Coding	5.67	DISEASES inferred ¹⁴
20	EDN1	Endothelin 1	Protein Coding	5.54	DISEASES inferred ¹⁴
21	MYH7	Myosin Heavy Chain 7	Protein Coding	5.51	DISEASES inferred ¹⁴
22	ADM	Adrenomedullin	Protein Coding	5.51	DISEASES inferred ¹⁴
23	INS	Insulin	Protein Coding	5.5	DISEASES inferred ¹⁴
24	MYBPC3	Myosin Binding Protein C3	Protein Coding	5.49	DISEASES inferred ¹⁴
25	ALB	Albumin	Protein Coding	5.48	DISEASES inferred ¹⁴
26	HSPB7	Heat Shock Protein Family B (Small) Member 7	Protein Coding	5.45	DISEASES inferred ¹⁴

Sources

Variations for Systolic Heart Failure

ClinVar genetic disease variations for Systolic Heart Failure:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TTN	NM_001267550.2(TTN):c.5668C>T (p.Arg1890Cys)	SNV	Likely Benign	47210	rs146496197	GRCh37: 2:179640923-179640923 GRCh38: 2:178776196-178776196
2	DSP	NM_004415.4(DSP):c.8300C>A (p.Thr2767Asn)	SNV	Benign	44963	rs34884895	GRCh37: 6:7585795-7585795 GRCh38: 6:7585562-7585562
3	DTNA	NM_001386795.1(DTNA):c.1438C>A (p.Pro480Thr)	SNV	Benign	46411	rs77320474	GRCh37: 18:32431798-32431798 GRCh38: 18:34851834-34851834
4	DSG2	NM_001943.5(DSG2):c.1543G>A (p.Val515Ile)	SNV	Benign	36010	rs2230235	GRCh37: 18:29116284-29116284 GRCh38: 18:31536321-31536321
5	ANKRD1	NM_014391.3(ANKRD1):c.827C>T (p.Ala276Val)	SNV	Benign	45639	rs35550482	GRCh37: 10:92675322-92675322 GRCh38: 10:90915565-90915565

Sources

Expression for Systolic Heart Failure

Search GEO for disease gene expression data for Systolic Heart Failure.

Sources

Pathways for Systolic Heart Failure

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cardiac conduction ⁶⁶ Show member pathways Classical Kir channels ⁶⁶ Ion homeostasis ⁶⁶ Ion transport by P-type ATPases ⁶⁶ Muscle contraction ⁶⁶ Phase 1 - inactivation of fast Na+ channels ⁶⁶ Phase 2 - plateau phase ⁶⁶ Phase 3 - rapid repolarisation ⁶⁶ Phase 4 - resting membrane potential ⁶⁶ Physiological factors ⁶⁶ Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) ⁶⁶ Tandem pore domain halothane-inhibited K+ channel (THIK) ⁶⁶ Tandem pore domain potassium channels ⁶⁶ TWIK related potassium channel (TREK) ⁶⁶ TWIK-related alkaline pH activated K+ channel (TALK) ⁶⁶ TWIK-related spinal cord K+ channel (TRESK) ⁶⁶ TWIK-releated acid-sensitive K+ channel (TASK) ⁶⁶	12.37	TTN TNNT2 TNNI3 PDE5A MYH6 MME
2	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.56	TNNT2 TNNI3 IL6
3	Acute viral myocarditis ⁷⁴	11.42	MYH6 IL6 EDN1
4	Cardiac progenitor differentiation ⁷⁴	11.22	TNNT2 TNNI3 MYH6
5	Striated muscle contraction pathway ⁷⁴ Show member pathways Striated Muscle Contraction ⁶⁶	11.13	TTN TNNT2 TNNI3 MYH6
6	ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE inhibitor pathway ⁷⁴ Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Conversion of angiotensinogen to angiotensin II ⁷⁴ Defective SERPING1 causes hereditary angioedema ⁶⁶ Downregulation of ACE2 by SARS-CoV-2 spike protein ⁷⁴ Kinin-Kallikrein pathway ⁷⁴ Non-classical role of vitamin D ⁷⁴ RAS and bradykinin pathways in COVID-19 ⁷⁴ Renin-angiotensin-aldosterone system (RAAS) ⁷⁴ SARS-CoV-2 and ACE2 receptor: molecular mechanisms ⁷⁴	11.08	REN NR3C2 MME AGTR1 ACE
7	Mitochondrial immune response to SARS-CoV-2 ⁷⁴ Show member pathways SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction ⁷⁴	11.02	IL6 AGTR1 ACE

Sources

GO Terms for Systolic Heart Failure

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.6	SERPINA3 REN NPPB MIR92B MIR423 MIR1306
2	cardiac myofibril	GO:0097512	9.56	TNNT2 TNNI3
3	myofibril	GO:0030016	9.46	TNNT2 TNNI3 MYH6
4	cardiac Troponin complex	GO:1990584	9.26	TNNT2 TNNI3

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	kidney development	GO:0001822	10.15	REN MME AGTR1 ACE
2	muscle contraction	GO:0006936	10.03	MYH6 TNNI3 TNNT2 TTN
3	sarcomere organization	GO:0045214	10.01	TTN TNNT2 MYH6
4	acute-phase response	GO:0006953	10	CRP IL6 SERPINA3
5	ventricular cardiac muscle tissue morphogenesis	GO:0055010	9.93	TNNT2 TNNI3 MYH6
6	bradykinin catabolic process	GO:0010815	9.88	MME ACE
7	regulation of vasoconstriction	GO:0019229	9.88	EDN1 AGTR1 ACE
8	body fluid secretion	GO:0007589	9.87	NPPB EDN1
9	regulation of systemic arterial blood pressure by renin-angiotensin	GO:0003081	9.86	AGTR1 ACE
10	vasoconstriction	GO:0042310	9.85	EDN1 CRP ACE
11	hormone catabolic process	GO:0042447	9.81	MME ACE
12	substance P catabolic process	GO:0010814	9.8	MME ACE
13	renin-angiotensin regulation of aldosterone production	GO:0002018	9.78	REN AGTR1
14	cardiac muscle contraction	GO:0060048	9.76	TTN TNNT2 TNNI3 MYH6
15	amyloid-beta metabolic process	GO:0050435	9.73	ACE MME REN
16	striated muscle contraction	GO:0006941	9.72	TTN TNNI3 MYH6
17	blood vessel diameter maintenance	GO:0097746	9.5	NPPB EDN1 AGTR1 ACE
18	regulation of blood pressure	GO:0008217	9.28	REN NPPB MYH6 EDN1 ACE